Extended Data Fig. 6. Overall tumor neoantigen burden is imperfectly correlated with clonal burden and ICB response in human MMRd cancer.
(a-d) Total clonal (CCF = 0.75 to 1.0) and subclonal (CCF = 0 to 0.5) tumor neoantigen burden (TNB) (a-b) and ITH index (subclonal to clonal neoantigen ratio) (c-d) in patients with objective response (OR) versus nonresponse (NR) in separated analyses of Bortolomeazzi trial50 (a,c) and Kwon trial35 (b,d). (e-g) TNB, regardless of clonality, in combined analysis (e) and separated analyses of Bortolomeazzi (f) and Kwon (g) trials. (h) Pearson correlation of overall versus clonal TNB across both studies, with correlation outliers circled in red. (i-j) Progression free survival of patients separated by upper versus lower quartiles of overall TNB (i) and clinical study (j). Number of patients from each study is indicated under plots. Significance in (a-g) was assessed by Wilcoxon Rank Sum test, and in (i-j) was assessed by Cox proportional hazards regression, with clinical trial study as a covariate in (i).